In 2018, John F. Milligan earned $4.93M in total compensation at Gilead Sciences, including $1.59M salary and $3.34M bonus. Most recently acquired 22,821 shares in Jun 2024. Currently holds stock worth $194.18M. Has donated $7.83M in stock to charitable causes. Led Gilead Sciences as CEO for 2 years.
Compensation History
Annual executive compensation data for John F. Milligan, including salary, bonuses, and stock awards.
Year
2018
Total Compensation
$4.93M
Salary
$1.59M
Bonus
$3.34M
Other
$0.00
Salary
$1.59MBoard Justification
The compensation philosophy aligns executive pay with company performance, emphasizing long-term value creation and retention of key executives.
Bonus
$3.34MBoard Justification
Annual bonus based solely on corporate performance, achieving 140% of target due to strong financial and operational performance.
Other Compensation
$0.00Board Justification
No other compensation was reported for 2018.
Restricted Stock
Board Justification
No stock awards vested in 2018 as the focus was on performance shares and options that were not yet vested.
Performance Metrics
Corporate performance metrics included product pipeline development, financial results, and organizational achievements.
John F. Milligan
Ex-CEO of Gilead Sciences
Education
Doctorate in Biochemistry from the University of Illinois
Field of Expertise
Finance & Banking - Finance
Sector of Economy
Healthcare
Born
January 1, 1962 - 63 years ago
CEO of Gilead Sciences for
2 years 9 months (Mar 2016 - Dec 2018)
Previous Experience
Executive Vice President and Chief Financial Officer at Gilead Sciences
Other Gilead Sciences CEOs
Holdings
Track John F. Milligan's stock holdings and portfolio value over time.
Total Stock Sold
$324.42M
$324.42M
4,054,412 GILD shares
What if they kept their stock?
If John F. Milligan didn't sell their stock, today they would have:
Extra GILD4,054,412 shares worth $496.34M.
This is 52.99% and $171.92M more than what they got when they sold the stock.
Charitable Transactions
64,000 shares
GILD
Recent Charitable Transactions
64,000 shares
GILD
May 12, 2014
Charity
Insider Trading
John F. Milligan's recent stock transactions, purchases, and sales filed with the SEC.
22,821 shares
PACB
Jun 18, 2024
Received
$1.17M
GILD at $20.78/share
Feb 15, 2018
Received
$16.03M
GILD at $72.88/share
Nov 13, 2017
Sale
$303.57K
GILD at $19.78/share
Feb 15, 2017
Received
$5.44M
GILD at $77.74/share
Sep 6, 2016
Sale
$4.97M
GILD at $70.94/share
Aug 1, 2016
Sale
$9.48M
GILD at $84.62/share
Jul 5, 2016
Sale
$9.73M
GILD at $86.92/share
Jun 6, 2016
Sale
$9.82M
GILD at $87.70/share
May 2, 2016
Sale
$10.61M
GILD at $94.71/share
Apr 4, 2016
Sale
Rivals
Compare John F. Milligan with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
2022 Compensation
Stock
$10.64M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Total Holdings
$50.74M
Marianne De Backer, MSc, Ph.D., MBA
CEO of Vir Biotechnology, Inc.
2023 Compensation
Stock
$5.80M
Salary
$675.00K
Bonus
$855.36K
Other
$437.18K
Total Holdings
$556.68K
John L. Higgins
CEO of Ligand Pharmaceuticals
2022 Compensation
Stock
$0.00
Salary
$730.46K
Bonus
$0.00
Other
$0.00
Total Holdings
$5.64M